Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

TONIX Pharmaceuticals to Present at the New York Society of Security Analysts’ 15th Annual Biotech and Specialty Pharmaceuticals Conference on November 30, 2011

November 21, 2011 • 6:05 AM EST

Tonix Pharmaceuticals Receives FDA Clearance to Initiate a Pharmacokinetic Study of TNX-102 For Fibromyalgia

November 18, 2011 • 7:30 AM EST

Tamandare Explorations Inc. Announces Name Change to Tonix Pharmaceuticals Holding Corp.

October 20, 2011 • 9:00 AM EDT

TONIX Pharmaceuticals and Tamandare Explorations Announce Completion of Share Exchange Transaction and Private Placement

October 14, 2011 • 9:00 AM EDT

Tonix Pharmaceuticals' Bedtime Very Low Dose Cyclobenzaprine Study Featured in Journal of Rheumatology

September 7, 2011 • 9:00 AM EDT

Tonix Pharmaceuticals Elects Charles Mather to its Board of Directors

August 17, 2011 • 9:00 AM EDT

Tonix Pharmaceuticals Elects Harvey Moldofsky, M.D., to its Scientific Advisory Board

June 20, 2011 • 9:00 AM EDT

TONIX Pharmaceuticals Presents Findings on the Effects of Bedtime Very Low Dose (VLD) Cyclobenzaprine (CBP) on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome

June 16, 2011 • 9:00 AM EDT

News / Press Releases : Press Releases